CY1122352T1 - Φαρμακευτικη συνθεση περιεχοντας μιραβεγρονη - Google Patents

Φαρμακευτικη συνθεση περιεχοντας μιραβεγρονη

Info

Publication number
CY1122352T1
CY1122352T1 CY20191101276T CY191101276T CY1122352T1 CY 1122352 T1 CY1122352 T1 CY 1122352T1 CY 20191101276 T CY20191101276 T CY 20191101276T CY 191101276 T CY191101276 T CY 191101276T CY 1122352 T1 CY1122352 T1 CY 1122352T1
Authority
CY
Cyprus
Prior art keywords
miravegron
pharmaceutical composition
composition containing
miravegrone
ready
Prior art date
Application number
CY20191101276T
Other languages
English (en)
Inventor
Seiji Takae
Toshiro Sakai
Yuki Kasashima
Yurina ANSEI
Tsuyoshi Kiyota
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of CY1122352T1 publication Critical patent/CY1122352T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Να παρασχεθεί: (1) ένα υγρό τροποποιημένης αποδέσμευσης (εναιώρημα) περιέχοντας μιραβεγρόνη, (2) μια έτοιμη-προς-εναιώρηση φαρμακευτική σύνθεση περιέχοντας μιραβεγρόνη, και (3) μια περιέχουσα μιραβεγρόνη φαρμακευτική σύνθεση που δεν παράγει μη-διαλελυμένους σβόλους, ακόμη και όταν εναιωρείται κατά τον χρόνο χρήσης. Η παρούσα εφεύρεση σχετίζεται με μια φαρμακευτική σύνθεση περιέχοντας ένα σύμπλοκο μιραβεγρόνης ή ενός φαρμακευτικώς αποδεκτού άλατος εξ αυτής με νατριούχο σουλφονικό πολυστυρένιο.
CY20191101276T 2015-03-31 2019-12-04 Φαρμακευτικη συνθεση περιεχοντας μιραβεγρονη CY1122352T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015073911A JP2018090490A (ja) 2015-03-31 2015-03-31 ミラベグロン含有医薬組成物
PCT/JP2016/060745 WO2016159267A1 (ja) 2015-03-31 2016-03-31 ミラベグロン含有医薬組成物

Publications (1)

Publication Number Publication Date
CY1122352T1 true CY1122352T1 (el) 2021-01-27

Family

ID=57005157

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101276T CY1122352T1 (el) 2015-03-31 2019-12-04 Φαρμακευτικη συνθεση περιεχοντας μιραβεγρονη

Country Status (14)

Country Link
US (1) US10058536B2 (el)
EP (1) EP3278801B1 (el)
JP (1) JP2018090490A (el)
CY (1) CY1122352T1 (el)
DK (1) DK3278801T3 (el)
ES (1) ES2760673T3 (el)
HR (1) HRP20192213T1 (el)
HU (1) HUE046729T2 (el)
LT (1) LT3278801T (el)
PL (1) PL3278801T3 (el)
PT (1) PT3278801T (el)
RS (1) RS59626B1 (el)
SI (1) SI3278801T1 (el)
WO (1) WO2016159267A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6713734B2 (ja) * 2015-07-02 2020-06-24 三栄源エフ・エフ・アイ株式会社 粉体組成物のダマの形成を抑制する方法
SG11202008233WA (en) * 2018-02-28 2020-09-29 Sumitomo Dainippon Pharma Co Ltd Aqueous suspension pharmaceutical preparation with controlled dissolution
WO2019167977A1 (ja) * 2018-02-28 2019-09-06 大日本住友製薬株式会社 水性懸濁型医薬製剤
KR102067261B1 (ko) * 2018-03-13 2020-01-16 충북대학교 산학협력단 미라베그론을 유효 성분으로 포함하는 서방형의 약학 조성물 및 이의 제조방법
WO2022006336A1 (en) * 2020-07-01 2022-01-06 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists
US11311518B1 (en) * 2021-06-29 2022-04-26 Jubilant Pharma Holdings Inc. Parenteral dosage form of β3 adrenoreceptor agonists
CN114617881A (zh) * 2022-02-19 2022-06-14 苏州海景医药科技有限公司 一种米拉贝隆组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2985714B2 (ja) * 1995-03-20 1999-12-06 栗田工業株式会社 抗菌性組成物
JP3193706B2 (ja) 1997-10-17 2001-07-30 山之内製薬株式会社 アミド誘導体又はその塩
US6514492B1 (en) * 1999-07-14 2003-02-04 Schering-Plough Veterinary Corporation Taste masking of oral quinolone liquid preparations using ion exchange resins
CA2379987A1 (en) 1999-07-29 2001-02-08 Roxane Laboratories, Inc. Opioid sustained-released formulation
JP3795365B2 (ja) 2001-09-28 2006-07-12 和光堂株式会社 服薬補助食品
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
ATE500827T1 (de) 2002-11-07 2011-03-15 Astellas Pharma Inc Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff
JP4211668B2 (ja) 2004-04-21 2009-01-21 キユーピー株式会社 ゾル状又はゲル状食品調製用粉末組成物
CN1879610A (zh) * 2006-04-03 2006-12-20 哈尔滨工业大学 口服多肽药物缓释微胶囊的制备方法
JP3930897B1 (ja) 2006-08-16 2007-06-13 太陽化学株式会社 粘度発現性を改良した増粘用組成物
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2013147134A1 (ja) * 2012-03-30 2013-10-03 アステラス製薬株式会社 ミラベグロン含有医薬組成物

Also Published As

Publication number Publication date
HUE046729T2 (hu) 2020-03-30
PL3278801T3 (pl) 2020-03-31
SI3278801T1 (sl) 2020-01-31
EP3278801A1 (en) 2018-02-07
EP3278801B1 (en) 2019-11-13
US10058536B2 (en) 2018-08-28
DK3278801T3 (da) 2019-12-16
LT3278801T (lt) 2020-01-10
EP3278801A4 (en) 2018-11-14
HRP20192213T1 (hr) 2020-03-20
WO2016159267A1 (ja) 2016-10-06
RS59626B1 (sr) 2020-01-31
US20180036288A1 (en) 2018-02-08
JP2018090490A (ja) 2018-06-14
ES2760673T3 (es) 2020-05-14
PT3278801T (pt) 2019-12-18

Similar Documents

Publication Publication Date Title
CY1122352T1 (el) Φαρμακευτικη συνθεση περιεχοντας μιραβεγρονη
CY1122695T1 (el) Αλας toy omecamtiv mecarbil και διαδικασια για την παρασκευη αλατος
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
EA201790785A1 (ru) Производные тетрагидроизохинолина
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
EA201691579A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
EA201790649A1 (ru) Бензилзамещенные индазолы в качестве ингибиторов bub 1
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
CL2017000270A1 (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias.
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
ECSP16074478A (es) Compuestos novedosos
CY1124655T1 (el) Κρυσταλλικες μορφες και μορφες αλατος ενωσεων οι οποιες ειναι αγωνιστες του ppar
MA41341A (fr) Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
EA201790655A1 (ru) Новые активаторы растворимой гуанилатциклазы и их применение
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
BR112016028639A2 (pt) composição de tintura de cabelo
UA111434C2 (uk) Фармацевтична композиція, що містить фімасартан і гідрохлортіазид
CY1122387T1 (el) Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
TR201901516T4 (tr) Nöroprotektif ajanlar ve bunların kullanımları.
EA201991855A1 (ru) Амин- или (тио)амидсодержащие модуляторы печеночных x-рецепторов (lxr)
CY1122334T1 (el) Νεες κρυσταλλικες mopφeς του αλατος μονονατριου της φορμασουλφουρονης